Sartorius to Acquire Danaher’s Life Science Portfolio for $750M

 Sartorius to Acquire Danaher’s Life Science Portfolio for $750M

Sartorius to Acquire Danaher’s Life Science Portfolio for $750M

Shots:

  • The life science portfolio to be acquired includes label-free biomolecular characterization (FortéBio), chromatography hardware and resins, and microcarriers (SoloHill) businesses. The proposed transaction follows Danaher’s GE Biopharma business and related regulatory approval
  • The transaction is expected to be completed in Q1’20 and will strengthen Sartorius’ presence in bioanalytics and bioprocessing segments with the acquisition of Danaher’s life science platform businesses
  • Danaher’s FortéBio comprises protein analysis instruments, biosensors and reagents, used in drug discovery while its SoloHill includes microcarrier technology and particle validation standards used in cell culture and other bioprocesses

Click here to­ read full press release/ article | Ref: Businesswire | Image: MPO-mag

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post